Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,916.00    12.50 (0.66%)
Bid:
1,916.00
Ask:
1,916.50
Spread: 0.50 (0.026%)
Market Cap: £76.81b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Glaxosmithkline News

LONDON MARKET OPEN: FTSE 100 falls; retail sales plunge in April
24 May 2024

LONDON MARKET OPEN: FTSE 100 falls; retail sales plunge in April

(Alliance News) - Stock prices in London opened lower on Friday, with sentiment hurt across the globe.

TOP NEWS: GSK celebrates Illinois jury verdict in Valadez case
24 May 2024

TOP NEWS: GSK celebrates Illinois jury verdict in Valadez case

(Alliance News) - GSK PLC on Friday welcomed the jury verdict in the Valadez case in Illinois state court, which found in GSK's favour in the first Za...

LONDON BRIEFING: UK retail sales fall amid wet April; Co-Op Bank deal
24 May 2024

LONDON BRIEFING: UK retail sales fall amid wet April; Co-Op Bank deal

(Alliance News) - Stocks are called to open lower on Friday, following New York lower, as hopes of interest rate cuts have come into question.

Jury rules in favour of GSK in Zantac trial
24 May 2024

Jury rules in favour of GSK in Zantac trial

(Sharecast News) - A court in Illinois has ruled in favour of GSK in the first Zantac case to go to trial, the UK drugs giant confirmed on Friday.

Zantac not a cause of woman’s cancer, jury says in first trial over drug
23 May 2024

Zantac not a cause of woman’s cancer, jury says in first trial over drug

CHICAGO, May 23 (Reuters) - A jury in Chicago on Thursday rejected an Illinois woman’s claim that the now discontinued heartburn drug Zantac caused ...

AstraZeneca aims for $80 bln in total revenue by 2030
21 May 2024

AstraZeneca aims for $80 bln in total revenue by 2030

Sees $80 bln in 2030 revenue by 2030 *

GSK's depemokimab asthma treatment meets endpoints in latest trials
21 May 2024

GSK's depemokimab asthma treatment meets endpoints in latest trials

(Alliance News) - GSK PLC on Tuesday announced positive results from trials of depemokimab, an "ultra-long-acting biologic" that could simplify treatm...